Clinical trials: Genetic Mutation
MEN1 Gene Mutation
Leflunomide Treatment for MEN1 Patients - the LUMEN1 Trial
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder due to mutations in the tumor suppressor gene MEN1 with the corresponding gen product menin.
- Trial name
- LUMEN1 (NCT05605587)
- Testing
- Leflunomide 20 mg
- Where
- Switzerland
- Volunteers
- 3 people
- Sponsor
- University Hospital, Basel, Switzerland
Non-small Cell Lung Cancer, Colorectal Carcinoma
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
- Trial name
- NCT06218914
- Testing
- NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
NSCLC
Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation
This study will be performed as a local multicenter, randomized, phase III clinical study. It will compare the adjuvant chemotherapy in Stage IB-IIIA NSCLC with common EGFR mutation (Exon 19 deletion or L858R) who underwent total…
- Trial name
- NCT02795884
- Testing
- intercalation therapy using pemetrexed, cisplatin and erlotinib, Vinorelbine, cisplatin
- Sponsor
- Yonsei University
Refractory Solid Tumors
Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors
This is a pilot study of sorafenib in patients with BRAF Mutation Refractory Solid Tumors. This study is a single-arm, pilot study of sorafenib in patients with Refractory Solid Tumors harboring BRAF Mutation Sorafenib 400 mg…
- Trial name
- NCT02450149
- Testing
- sorafenib
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- Samsung Medical Center
Lung Cancer
Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma
Both pemetrexed and erlotinib are second-line treatment options for patients with advanced non-small cell lung cancer. It is controversial that whether it is necessary to detect epidermal growth factor receptor (EGFR) mutation…
- Trial name
- NCT01565538
- Testing
- Erlotinib, Pemetrexed
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Si-Yu Wang
Non-small Cell Lung Cancer (NSCLC)
Selumetinib in Combination With Gefitinib in NSCLC Patients
This is an open-label, non-randomized, multicenter phase Ib/II study, which is composed of a phase Ib dose escalation part and a phase II dose expansion part.
- Trial name
- NCT02025114
- Testing
- selumetinib
- Where
- 3 sites in Taiwan
- Volunteers
- 34 people
- Sponsor
- National Taiwan University Hospital
Non-Small-Cell Lung Carcinoma
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
This is an open label, prospective, multicenter, non-comparative study to assess the safety and effectiveness of Tabrecta® (Capmatinib) in real world setting.
- Trial name
- NCT05703516
- Testing
- Capmatinib
- Where
- 10 sites in South Korea
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
This randomized clinical trial studies a group-based lifestyle intervention or usual care in measuring biomarker levels in participants at high risk for breast cancer.
- Conditions
- Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
- Trial name
- DEEM (NCT01874184)
- Testing
- counseling intervention, behavioral dietary intervention, exercise intervention
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Washington
MSS, RAS-mutant Colorectal Cancer
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
This is a multicenter, open-label, Phase 1B/2 study to evaluate the safety and assess the preliminary anti-tumor activity of binimetinib administered in combination with nivolumab or nivolumab + ipilimumab in adult patients with…
- Trial name
- NCT03271047
- Testing
- binimetinib, nivolumab, ipilimumab
- Where
- 50 sites in United States, Belgium and 3 more
- Volunteers
- 75 people
- Sponsor
- Pfizer
Acute Myeloid Leukemia With FLT3/ITD Mutation
A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants
This study plans to enroll 45 (Groups A, B, and C) to 75 healthy participants (including the sample size of other potential dose groups). The participants will be divided into three dose groups: 37.5 mg, 75 mg, and 150 mg.
- Trial name
- XY0206-CQT (NCT07162116)
- Testing
- XY0206, Moxifloxacin (400 mg)
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Carcinoma, Non-Small-Cell Lung
A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples
EGFR mutations plays an essential role in EGFR-TKIs treatment. However, for some patients, tissue samples are not available. The purpose of this study is to determine whether blood sample is feasible for EGFR mutation…
- Trial name
- NCT01382992
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking Union Medical College Hospital
Non Small Cell Lung Cancer, Liquid Biopsy
ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)
The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for…
- Conditions
- Non Small Cell Lung Cancer, Liquid Biopsy, Tyrosine Kinase Inhibitor
- Trial name
- START-TKI (NCT05221372)
- Where
- Netherlands
- Volunteers
- 1,300 people
- Sponsor
- Erasmus Medical Center
Adenocarcinoma of Lung Metastatic to Brain
Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases
The goal of this clinical trial is to learn if furmonertinib plus anlotinib works to treat participants with lung adenocarcinoma with EGFR mutations and brain metastases.
- Trial name
- LungBrain001 (NCT06483672)
- Testing
- Furmonertinib, Anlotinib
- Volunteers
- 27 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
This was a Phase II, multicenter, non-randomized, open-label study to assess the efficacy, safety, and tolerability of dabrafenib administered as a single agent and in combination with trametinib in stage IV disease to subjects…
- Trial name
- NCT01336634
- Testing
- Dabrafenib, Trametinib
- Where
- 50 sites in United States, France and 9 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Myelofibrosis
Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation Levels
This study was an observational study, and about 40 patients with intermediate and high risk myelofibrosis who had participated in any previous clinical study of Gecacitinib hydrochloride and were still receiving Gecacitinib…
- Trial name
- NCT07342712
- Where
- China
- Volunteers
- 40 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Primary Ciliary Dyskinesia (PCD)
Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance
This is a multi-dose study with RCT1100 and is designed to provide safety, tolerability and preliminary efficacy data for future clinical studies.
- Trial name
- NCT06633757
- Testing
- RCT1100
- Where
- 3 sites in United States, Denmark and 1 more
- Volunteers
- 14 people
- Sponsor
- ReCode Therapeutics
Hereditary Elliptocytosis (HE), Hereditary Pyropoikilocytosis (HPP)
A Novel Mutation of the Spectrin Gene
The purpose of this study is to find a gene or its mutation (an altered gene) that puts individuals at risk for developing HE or HPP.
- Trial name
- NCT00723567
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Utah
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation
The Drugs Controller General of India (DCGI) has granted approval for Asciminib film-coated 40 mg tablets on 20 Oct 2023 with the condition to perform a Phase IV clinical study in Indian patients with Philadelphia…
- Trial name
- ASC4INDIA (NCT06427811)
- Testing
- Asciminib
- Where
- 10 sites in India
- Volunteers
- 85 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia (CML)
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
The objective of this Phase II study is to assess the potential of asciminib in managing CML-CP or CML-AP in patient carrying the T315I mutation.
- Trial name
- ASC4TARGET (NCT06514534)
- Testing
- ABL001/Asciminib
- Where
- 6 sites in France
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Lung Neoplasms
Cryotherapy Combine Icotinib for Advanced NSCLC Treatment
This trial is to designed to assess the efficacy and safety of Cryotherapy combine with Icotinib for Advanced NSCLC Patients harboring EGFR mutation.
- Trial name
- NCT02744664
- Testing
- Cryotherapy, Icotinib
- Volunteers
- 60 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.